Flavored, Oral Irinotecan (VAL-413) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Conditions:   Solid Tumors;   Neuroblastoma;   Rhabdomyosarcoma;   Ewing Sarcoma;   Hepatoblastoma;   Medulloblastoma Interventions:   Drug: VAL-413;   Drug: Temozolomide Sponsor:   Valent Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials